Biljana Parapid
Overview
Explore the profile of Biljana Parapid including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
111
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Manzo-Silberman S, Hawranek M, Banerjee S, Kaluzna-Oleksy M, Alasnag M, Paradies V, et al.
Eur Heart J Open
. 2024 Nov;
4(6):oeae087.
PMID: 39507804
Cardiovascular diseases are the leading cause of death among women, and the incidence among younger women has shown the greatest increase over the last decades, in particular for acute myocardial...
2.
Lalic N, Bojovic M, Bursac D, Bokan D, Ceriman Krstic V, Kuhajda I, et al.
Pathol Oncol Res
. 2024 Jul;
30:1611717.
PMID: 39071547
By 2021, the FDA approved the use of the drugs pembrolizumab and atezolizumab in the first-line treatment of patients with high positivity of programmed death ligand-1 (PD-L1) in locally advanced...
3.
Lalic N, Bojovic M, Ivanov O, Licina J, Popevic S, Stjepanovic M, et al.
Medicina (Kaunas)
. 2024 Mar;
60(3).
PMID: 38541177
: Advanced lung cancer is usually manifested by endoluminal tumor propagation, resulting in central airway obstruction. The objective of this study is to compare the high dose rate brachytherapy treatment...
4.
Parapid B, Kanjuh V
Arq Bras Cardiol
. 2023 Sep;
120(7):e20230426.
PMID: 37672467
No abstract available.
5.
Obstructive Sleep Apnea and Cardiovascular Risk: The Role of Dyslipidemia, Inflammation, and Obesity
Zdravkovic M, Popadic V, Klasnja S, Milic N, Rajovic N, Divac A, et al.
Front Pharmacol
. 2022 Jul;
13:898072.
PMID: 35784707
The present study aimed to establish the role of lipid abnormalities and inflammatory markers for developing cardiovascular risk, as well as to address the importance of obesity as a common...
6.
Kemaloglu Oz T, Cader F, Dakhil Z, Parapid B, Kadavath S, Bond R, et al.
Minerva Cardiol Angiol
. 2022 Feb;
70(6):641-651.
PMID: 35212510
The challenges to academic and professional development and career advancement of women in cardiology (WIC), imposed by the pandemic, not only impinge the female cardiologists' "leaky pipeline" but also make...
7.
Gulati M, Hendry C, Parapid B, Mulvagh S
Eur Cardiol
. 2022 Jan;
16:e52.
PMID: 35024054
Although cardiovascular disease (CVD) is the leading cause of mortality in women globally, cardiovascular care for women remains suboptimal, with poorer outcomes than for men. During the past two decades,...
8.
Gelbenegger G, Schoergenhofer C, Jilma B, Gager G, Dizdarevic A, Mamas M, et al.
Clin Pharmacol Ther
. 2021 Mar;
110(2):424-431.
PMID: 33668076
Dual antiplatelet therapy (DAPT) and subsequent P2Y inhibitor monotherapy, particularly ticagrelor, is an emerging treatment strategy in patients undergoing percutaneous coronary intervention (PCI). This meta-analysis was designed to investigate whether...
9.
Bond R, Gaither K, Nasser S, Albert M, Ferdinand K, Njoroge J, et al.
Circ Cardiovasc Qual Outcomes
. 2021 Feb;
14(2):e007643.
PMID: 33563007
Following decades of decline, maternal mortality began to rise in the United States around 1990-a significant departure from the world's other affluent countries. By 2018, the same could be seen...
10.
Aleksandric S, Djordjevic-Dikic A, Beleslin B, Parapid B, Teofilovski-Parapid G, Stepanovic J, et al.
Int J Cardiol
. 2016 Oct;
225:37-45.
PMID: 27710800
Background: To consider hemodynamic assessment of myocardial bridging (MB) adequate, it is believed that inotropic stimulation with dobutamine should be estimated because its dynamic nature depends on the degree of...